FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005017217> ?p ?o ?g. }

• W2005017217 endingPage "83" @default.
• W2005017217 startingPage "76" @default.
• W2005017217 abstract "CI-1031 (ZK-807834) is a novel, synthetic factor Xa (FXa) inhibitor with a Ki of 0.11 nM against human FXa. In human plasma in vitro, CI-1031 doubled PT and aPTT at 0.23 and 0.49 microM, respectively. The in vivo antithrombotic effect of CI-1031 was evaluated in a veno-venous shunt model of thrombosis in anesthetized rabbits. After thrombus formation was verified in the first shunts, rabbits received either vehicle or CI-1031 intravenously (bolus injection of 60, 240, or 480 microg/kg followed by an infusion of 2, 8, or 16 microg/kg/min for 140 min, respectively). The second shunts were inserted after 20 min of infusion of CI-1031 or vehicle. CI-1031 dose-dependently prolonged time to occlusion (TTO) in the second shunts (35 +/- 21, 62 +/- 24, and 120 +/- 0 min for the three dose groups, respectively, vs. 10 +/- 1 min for vehicle). Thrombus mass (TM) was reduced in a dose-dependent manner by CI-1031 (42 +/- 7, 27 +/- 6, and 18 +/- 4 mg vs. 50 +/- 4 mg for vehicle). Maximal TM reduction was 70% with an IC(50) of 0.6 microg/ml. Among all the coagulation parameters tested, PT had the best correlation with plasma CI- 1031 concentration (r = 0.97). Ex vivo plasma anti-FXa activity was also well correlated with plasma concentration of CI-1031 and with PT (r = 0.96 and 0.98, respectively). These results indicate that CI-1031, which is currently undergoing clinical evaluation, is an effective antithrombotic compound with a favorable efficacy-to-bleeding ratio. In addition, CI-1031 concentration in plasma can be monitored using PT or anti-Xa assays, thereby providing reliable methods to ensure safe and accurate dose titration of CI-1031." @default.
• W2005017217 created "2016-06-24" @default.
• W2005017217 creator A5000711657 @default.
• W2005017217 creator A5002634572 @default.
• W2005017217 creator A5020394864 @default.
• W2005017217 creator A5036466656 @default.
• W2005017217 creator A5054079483 @default.
• W2005017217 creator A5057924226 @default.
• W2005017217 creator A5059472639 @default.
• W2005017217 creator A5067352271 @default.
• W2005017217 creator A5068689762 @default.
• W2005017217 creator A5077652159 @default.
• W2005017217 date "2002-01-01" @default.
• W2005017217 modified "2023-09-26" @default.
• W2005017217 title "Assessment of ex vivo Pharmacodynamic Markers during Inhibition of Thrombosis by CI-1031 (ZK-807834), a Novel Direct Factor Xa Inhibitor" @default.
• W2005017217 cites W149105390 @default.
• W2005017217 cites W1581557633 @default.
• W2005017217 cites W164295419 @default.
• W2005017217 cites W1886476141 @default.
• W2005017217 cites W1907935103 @default.
• W2005017217 cites W1971800067 @default.
• W2005017217 cites W1996667418 @default.
• W2005017217 cites W2010280774 @default.
• W2005017217 cites W2011085863 @default.
• W2005017217 cites W2018000906 @default.
• W2005017217 cites W2021953458 @default.
• W2005017217 cites W2028870588 @default.
• W2005017217 cites W2041452587 @default.
• W2005017217 cites W2049970502 @default.
• W2005017217 cites W2049998445 @default.
• W2005017217 cites W2058257764 @default.
• W2005017217 cites W2058310514 @default.
• W2005017217 cites W2066458313 @default.
• W2005017217 cites W2070854435 @default.
• W2005017217 cites W2075196907 @default.
• W2005017217 cites W2081561904 @default.
• W2005017217 cites W2109289067 @default.
• W2005017217 cites W2114694439 @default.
• W2005017217 cites W2117966472 @default.
• W2005017217 cites W2138849164 @default.
• W2005017217 cites W2174643155 @default.
• W2005017217 cites W2201677742 @default.
• W2005017217 cites W2284651264 @default.
• W2005017217 cites W2313058008 @default.
• W2005017217 cites W2316460201 @default.
• W2005017217 cites W2319669995 @default.
• W2005017217 cites W2332995384 @default.
• W2005017217 cites W2335822722 @default.
• W2005017217 cites W2404430831 @default.
• W2005017217 cites W2413859883 @default.
• W2005017217 cites W2414788300 @default.
• W2005017217 cites W2415007657 @default.
• W2005017217 cites W2417105434 @default.
• W2005017217 cites W2777952450 @default.
• W2005017217 cites W3125065962 @default.
• W2005017217 doi "https://doi.org/10.1159/000056154" @default.
• W2005017217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11803247" @default.
• W2005017217 hasPublicationYear "2002" @default.
• W2005017217 type Work @default.
• W2005017217 sameAs 2005017217 @default.
• W2005017217 citedByCount "3" @default.
• W2005017217 countsByYear W20050172172012 @default.
• W2005017217 crossrefType "journal-article" @default.
• W2005017217 hasAuthorship W2005017217A5000711657 @default.
• W2005017217 hasAuthorship W2005017217A5002634572 @default.
• W2005017217 hasAuthorship W2005017217A5020394864 @default.
• W2005017217 hasAuthorship W2005017217A5036466656 @default.
• W2005017217 hasAuthorship W2005017217A5054079483 @default.
• W2005017217 hasAuthorship W2005017217A5057924226 @default.
• W2005017217 hasAuthorship W2005017217A5059472639 @default.
• W2005017217 hasAuthorship W2005017217A5067352271 @default.
• W2005017217 hasAuthorship W2005017217A5068689762 @default.
• W2005017217 hasAuthorship W2005017217A5077652159 @default.
• W2005017217 hasConcept C111113717 @default.
• W2005017217 hasConcept C112705442 @default.
• W2005017217 hasConcept C126322002 @default.
• W2005017217 hasConcept C150903083 @default.
• W2005017217 hasConcept C185592680 @default.
• W2005017217 hasConcept C202751555 @default.
• W2005017217 hasConcept C207001950 @default.
• W2005017217 hasConcept C26291073 @default.
• W2005017217 hasConcept C2777015399 @default.
• W2005017217 hasConcept C2781362458 @default.
• W2005017217 hasConcept C42219234 @default.
• W2005017217 hasConcept C43376680 @default.
• W2005017217 hasConcept C55493867 @default.
• W2005017217 hasConcept C71924100 @default.
• W2005017217 hasConcept C86803240 @default.
• W2005017217 hasConcept C98274493 @default.
• W2005017217 hasConceptScore W2005017217C111113717 @default.
• W2005017217 hasConceptScore W2005017217C112705442 @default.
• W2005017217 hasConceptScore W2005017217C126322002 @default.
• W2005017217 hasConceptScore W2005017217C150903083 @default.
• W2005017217 hasConceptScore W2005017217C185592680 @default.
• W2005017217 hasConceptScore W2005017217C202751555 @default.
• W2005017217 hasConceptScore W2005017217C207001950 @default.
• W2005017217 hasConceptScore W2005017217C26291073 @default.
• W2005017217 hasConceptScore W2005017217C2777015399 @default.

• next